The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 18, Issue 8, Pages 775-784
Publisher
Informa UK Limited
Online
2018-06-21
DOI
10.1080/14737140.2018.1489246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
- (2018) Emily Z. Keung et al. ANNALS OF SURGICAL ONCOLOGY
- How to use neoadjuvant medical treatment to maximize surgery in melanoma
- (2018) Teresa Amaral et al. Expert Review of Anticancer Therapy
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update
- (2018) Sandra L. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant therapy in melanoma: the next step?
- (2018) Paolo A Ascierto et al. LANCET ONCOLOGY
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
- (2018) Rodabe N Amaria et al. LANCET ONCOLOGY
- The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
- (2017) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant systemic therapy for regionally advanced melanoma
- (2017) James W. Jakub et al. JOURNAL OF SURGICAL ONCOLOGY
- Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases
- (2017) Mario Mandalà et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- (2017) Mark B. Faries et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma
- (2017) Robert H. I. Andtbacka et al. Journal of the National Comprehensive Cancer Network
- Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis
- (2016) Erin Cordeiro et al. ANNALS OF SURGICAL ONCOLOGY
- State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now
- (2016) Mary K. Tripp et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
- (2016) Priyadharsini Nagarajan et al. CLINICAL CANCER RESEARCH
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
- (2016) Ulrike Leiter et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
- (2015) Alexander M. Menzies et al. CANCER
- 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
- (2015) J. Larkin et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
- (2014) Rebecca L. Read et al. ANNALS OF SURGICAL ONCOLOGY
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
- (2014) Donald L. Morton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma
- (2013) Dale Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma
- (2012) Florentien E. M. in ʼt Hout et al. ANNALS OF SURGERY
- Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma
- (2012) James Wilmott et al. HISTOPATHOLOGY
- Population-Based 20-Year Survival Among People Diagnosed With Thin Melanomas in Queensland, Australia
- (2012) Adèle C. Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma
- (2011) Rajmohan Murali et al. ANNALS OF SURGERY
- Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database
- (2011) John F. Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants of survival in patients with brain metastases from cutaneous melanoma
- (2010) M Staudt et al. BRITISH JOURNAL OF CANCER
- Prognostic factors for survival in melanoma patients with brain metastases
- (2010) Michael A. Davies et al. CANCER
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
- (2010) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma
- (2008) Simone L. Van Es et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
- (2008) Alexander C. J. van Akkooi et al. ANNALS OF SURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started